Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832201 | 0.93 | PPID (0.52) | ATML3MBTL1LMNAKLKB1PPARA | |
| SCHEMBL14617704 | 0.89 | ATM (0.64) | ATML3MBTL1LMNAKLKB1PPARA | |
| SCHEMBL14617754 | 0.89 | ATM (0.64) | ATML3MBTL1LMNAKLKB1PPARA | |
| SCHEMBL15834863 | 0.87 | MAPT (0.48) | ATML3MBTL1KLKB1MAPTNPC1 | |
| SCHEMBL14617757 | 0.84 | ATM (0.65) | ATML3MBTL1LMNAKLKB1SMN1; SMN2 | |
| SCHEMBL15832202 | 0.84 | LMNA (0.48) | L3MBTL1LMNAPPARAALDH1A1 | |
| SCHEMBL15834851 | 0.82 | PTPN1 (0.52) | PPARA | |
| SCHEMBL12643651 | 0.82 | PPID (0.58) | ATML3MBTL1KLKB1SMN1; SMN2MAPT | |
| SCHEMBL2040860 | 0.82 | PPID (0.58) | ATML3MBTL1KLKB1SMN1; SMN2MAPT | |
| SCHEMBL2034518 | 0.82 | PPID (0.58) | ATML3MBTL1KLKB1PPIDLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | ATM 4698/4885L3MBTL1 3342/4885LMNA 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.